Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238166 | 0.86 | ALDH1A1 (0.70) | TDP1POLBRAB9AKMT2ACYP2C9 | |
| SCHEMBL10761462 | 0.79 | CYP2C9 (0.86) | TDP1POLBRAB9AKMT2ACYP2C9 | |
| SCHEMBL2016229 | 0.79 | MEN1 (0.63) | TDP1POLBRAB9AKMT2AHTR4 | |
| SCHEMBL26107773 | 0.79 | SMN1; SMN2 (0.69) | TDP1POLBRAB9AKMT2ACYP2C9 | |
| SCHEMBL1811001 | 0.79 | POLB (0.53) | TDP1POLBRAB9AKMT2AMEN1 | |
| SCHEMBL6164385 | 0.78 | RAB9A (0.80) | TDP1POLBRAB9AKMT2ACYP2C9 | |
| SCHEMBL13889089 | 0.78 | POLB (0.54) | TDP1POLBRAB9AKMT2AHTR4 | |
| SCHEMBL10757593 | 0.77 | CYP2C9 (0.83) | TDP1POLBRAB9AKMT2ACYP2C9 | |
| SCHEMBL1809205 | 0.77 | POLB (0.51) | TDP1POLBRAB9AKMT2ACYP2C9 | |
| SCHEMBL7487026 | 0.76 | KDM4E (0.68) | TDP1POLBKMT2AHTR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2025-09-23 | — | — | US | disclosed |
| US-20220296593-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296593-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | PCSK9, LDLR, CETP | TDP1 2651/4885POLB 4314/4885RAB9A 1742/4885 |
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | PCSK9, LDLR, CETP | TDP1 2817/4885POLB 4401/4885RAB9A 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.